Patients taking GLP-1 drugs lose weight faster, but they may experience side effects, such as nausea, vomiting, diarrhea, indigestion, fatigue, dizziness, and hypoglycemia, along with other potential adverse events
In head-to-head trials, tirzepatide demonstrated greater efficacy in glycemic control and weight reduction compared to semaglutide 1 mg (SURPASS-2)
Several factors shape your final monthly cost
16-18 Nausea is the most frequently reported AE among GLP-1 RAs, with rates ranging from 20% to 40% depending on the agent and dose
The program does not include scheduled visits, longitudinal care plans, or clinician relationships visible before enrollment
Beyond these interventions, The Beauty Bus provides an added support layer through its pharmaceutical-grade nutraceuticals